Ceftriaxone Efficacy for Mycobacterium avium Complex Lung Disease in the Hollow Fiber and Translation to Sustained Sputum Culture Conversion in Patients
The Journal of Infectious Diseases · 2024
DOI: 10.1093/infdis/jiad545 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Infectious Diseases, 2024. Verfasst von Devyani Deshpande und 5 weiteren Autor:innen. Beteiligte Einrichtung: Baylor University Medical Center, Dallas. Hauptthemen laut MEDLINE: Ceftriaxone, Mycobacterium avium Complex, Anti-Bacterial Agents, Sputum. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Non-Tuberculous Mycobacteria, Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIAID NIH HHS.
Abstract (Originalsprache)
Background
Only 35.6%–50.8% of patients with Mycobacterium avium complex (MAC) pulmonary disease achieve sustained sputum culture conversion (SSCC) on treatment with the azithromycin-ethambutol-rifabutin standard of care (SOC). We tested the efficacy of ceftriaxone, a β-lactam with a lung-to-serum penetration ratio of 12.18-fold.
Methods
We mimicked lung concentration-time profiles of 7 ceftriaxone once-daily doses for 28 days in the hollow fiber system model of intracellular MAC (HFS-MAC). Monte Carlo experiments were used for dose selection. We also compared once-daily ceftriaxone monotherapy to 3-drug SOC against 5 MAC clinical isolates in HFS-MAC using γ (kill) slopes, and translated to SSCC rates.
Results
Ceftriaxone killed 1.02–3.82 log10 colony-forming units (CFU)/mL, at optimal dose of 2 g once-daily. Ceftriaxone killed all 5 strains below day 0 versus 2 of 5 for SOC. The median γ (95% confidence interval [CI]) was 0.49 (.47–.52) log10 CFU/mL/day for ceftriaxone and 0.38 (.34–.43) log10 CFU/mL/day for SOC. In patients, the SOC was predicted to achieve SSCC rates (CI) of 39.3% (36%–42%) at 6 months. The SOC SSCC was 50% at 8.18 (3.64–27.66) months versus 3.58 (2.20–7.23) months for ceftriaxone, shortening time to SSCC 2.35-fold.
Conclusions
Ceftriaxone is a promising agent for creation of short-course chemotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Baylor University Medical Center, Dallas.
- Mathematical Modeling and AI Department, Praedicare Inc, Dallas.
- Department of Medicine, School of Medicine, University of Texas at Tyler.
- Department of Cellular and Molecular Biology, School of Medicine, University of Texas Health Science Center at Tyler.
- Hollow Fiber System and Experimental Therapeutics Laboratories, Praedicare Inc, Dallas, Texas.
ORCID-Profile: Tawanda Gumbo
Förderung
- Non-Tuberculous Mycobacteria
- Eunice Kennedy Shriver National Institute of Child Health and Human Development
- NIAID NIH HHS
- Thoracic Foundation
- Department of Pulmonary Immunology
- University of Texas System
- American Thoracic Foundation
- NICHD NIH HHS
Zitieren
APA
Deshpande, D., Magombedze, G., Boorgula, G. D., Chapagain, M., Srivastava, S., & Gumbo, T. (2024). Ceftriaxone Efficacy for Mycobacterium avium Complex Lung Disease in the Hollow Fiber and Translation to Sustained Sputum Culture Conversion in Patients. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiad545
Vancouver
Deshpande D, Magombedze G, Boorgula GD, Chapagain M, Srivastava S, Gumbo T. Ceftriaxone Efficacy for Mycobacterium avium Complex Lung Disease in the Hollow Fiber and Translation to Sustained Sputum Culture Conversion in Patients. The Journal of Infectious Diseases. 2024. doi:10.1093/infdis/jiad545
BibTeX
@article{Deshpande2024,
author = {Deshpande, Devyani and Magombedze, Gesham and Boorgula, Gunavanthi D and Chapagain, Moti and Srivastava, Shashikant and Gumbo, Tawanda},
title = {Ceftriaxone Efficacy for Mycobacterium avium Complex Lung Disease in the Hollow Fiber and Translation to Sustained Sputum Culture Conversion in Patients},
journal = {The Journal of Infectious Diseases},
year = {2024},
doi = {10.1093/infdis/jiad545}
}
EUVIMED